Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ergebnisse der LuPSMA-Studie zeigen hohe Ansprechraten mit geringer Toxizität und Schmerzlinderung

Results of the LuPSMA trial show high response rates with low toxicity and pain relief

  • 126 Accesses

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–91

  2. 2.

    Kratochwil C, Giesel FL, Stefanova M et al (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med 57:1170–1176

  3. 3.

    Heck MM, Retz M, D’Alessandria C et al (2016) Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol 196:382–391

Download references

Author information

Correspondence to Dr. med. S. Tschirdewahn.

Ethics declarations

Interessenkonflikt

S. Tschirdewahn und W. P. Fendler geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tschirdewahn, S., Fendler, W.P. Ergebnisse der LuPSMA-Studie zeigen hohe Ansprechraten mit geringer Toxizität und Schmerzlinderung. Urologe 57, 1494–1495 (2018). https://doi.org/10.1007/s00120-018-0808-y

Download citation